ClinicalTrials.Veeva
Menu

Find clinical trials for Lung Cancer in Baltimore, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Cancer
Small Cell Lung Carcinoma
Carcinoma
Colorectal Cancer
Squamous Cell Carcinoma of Head and Neck
Neoplasm Metastasis

Lung Cancer trials near Baltimore, MD, USA:

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osim ...

Enrolling
Metastatic Non-small Cell Lung Cancer
Drug: Osimertinib
Drug: Carboplatin

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Baltimore, Maryland, United States and 17 other locations

a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Baltimore, Maryland, United States and 83 other locations

This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung ca...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: DS-1062a

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Chevy Chase, Maryland, United States and 84 other locations

This phase II clinical trial will study the safety and efficacy of onvansertib to treat patients with small cell lung cancer (SCLC)...

Enrolling
Small-cell Lung Cancer
Small Cell Lung Carcinoma
Drug: Onvansertib

Phase 2

Taofeek Owonikoko

Baltimore, Maryland, United States and 1 other location

with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NS...

Enrolling
Advanced Lung Cancer
Biological: BNT327
Biological: BNT324

Phase 1, Phase 2

BioNTech
BioNTech

Fairfax, Virginia, United States and 19 other locations

the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung...

Active, not recruiting
Lung Cancer
Drug: Itacitinib
Drug: Osimertinib

Phase 1, Phase 2

Incyte
Incyte

Washington, District of Columbia, United States and 30 other locations

combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants.The main goals of this study are to:* E...

Enrolling
Limited Stage Small Cell Lung Cancer
Drug: Durvalumab
Drug: BMS-986489

Phase 2

SCRI Development Innovations

Fairfax, Virginia, United States and 25 other locations

Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common fo ...

Enrolling
Non-small Cell Lung Cancer
Drug: Pemetrexed
Biological: HER3-DXd

Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Baltimore, Maryland, United States and 36 other locations

Locations recently updated

with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Bethesda, Maryland, United States and 210 other locations

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Baltimore, Maryland, United States and 122 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems